Recce Pharmaceuticals includes a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by antibiotic-resistant superbugs.
Board of Directors
Dr John Prendergast
Executive Chairman
Dr. Prendergast, based in the US, is a renowned executive in the pharmaceutical industry. Currently serving as the Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and the Lead Director of Nighthawk Biosciences (NYSE: HHWK), he brings over three decades of expertise in the commercialisation of pharmaceutical technologies.
Dr. Prendergast has led the approval of three new drug applications and played a pivotal role in the successful sale of Vylessi® to Cosette Pharmaceuticals for USD $12M, marking a significant achievement in the pharmaceutical landscape.
James Graham
Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He was formerly Executive Director and has extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential. Mr Graham serves on Recce’s Board of Directors and has invested in almost every capital raise to date with a focus on expanding Recce’s commercial opportunities and clinical initiatives.
Michele Dilizia
Executive Director & Chief Scientific Officer
Ms Dilizia is a co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. She successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).
Dr Justin Ward
Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), MRACI, CChem, MPharm
Dr Ward is a qualified Chemist and Pharmacist with over 20 years of pharmaceutical and biotech industry experience in quality control, quality assurance, product research and development with leading pharmaceutical companies, including Pfizer. Dr Ward previously held a technical role with Pfizer, involving providing data for regulatory submissions to the FDA and TGA.
Dr Alan Dunton
Chief Medical Advisor & Non-Executive Director
Based in the US, Dr. Dunton, as the Director of Palatin Technologies, brings a wealth of experience with over three decades in senior pharmaceutical roles. Notably, he served as the President and Managing Director of the Janssen Research Foundation (J&J Research).
Dr. Dunton successfully advanced multiple blockbuster antibiotics through to commercialisation at Fortune 500 companies, such as J&J and Roche, where he played instrumental roles in shaping the commercial success of pharmaceutical products. Dr. Dunton played a key role in the recent sale of Vylessi® to Cosette Pharmaceuticals for USD $12M, continuing his track record of fostering advancements in drug development and successful commercialisation efforts.
Alistair McKeough
Non-Executive Director
Mr McKeough is an experienced executive and solicitor. Before being appointed as a non-executive director in 2022, Alistair served as Recce’s company secretary and he has been involved with the company since 2017. Alistair has extensive experience in a variety of private and listed corporations across many sectors, including professional services, technology, financial services, charities, health, biotech, childcare and education. Recent roles include Managing Director of a legal practice specialising in equity capital markets and advice to listed companies and as part of the senior leadership team at share registry, Automic Group.
Justin Reynolds
Outsourced CFO
Mr Reynolds is a Partner at Pitcher Partners Sydney. His experience with multinational companies has led him to developing expertise as an Outsourced Financial Controller.
Maggie Niewidok
Company Secretary
Senior Management
James Graham
Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He was formerly Executive Director and has extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential. Mr Graham has served on Recce’s Board of Directors for six years and has invested in almost every capital raise to date with a focus on expanding Recce’s commercial opportunities and clinical initiatives.
Michele Dilizia
Executive Director & Chief Scientific Officer
Ms Dilizia is a co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. She successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).
Dr Justin Ward
Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), MRACI, CChem, MPharm
Dr Ward is a qualified Chemist and Pharmacist with over 20 years of pharmaceutical and biotech industry experience in quality control, quality assurance, product research and development with leading pharmaceutical companies, including Pfizer. Dr Ward previously held a technical role with Pfizer, involving providing data for regulatory submissions to the FDA and TGA.
Arthur Kollaras
Principal Engineer & Head of Manufacturing
BSc, BEng (Chem), PhilEng (Enviro), MIEAust, MISPE
Daniel Astudillo
Head of Marketing
Mr Astudillo has ten years of expertise in pharmaceuticals and clinical trials sector. He specialises in crafting impactful digital marketing campaigns and effectively engaging key investors in the healthcare sector.
Thomas Jarrett
Quality Control Manager
Mr. Jarrett is an experienced Quality Control Manager with over 5 years of expertise in overseeing QC functions and taking an active role in Quality Assurance programs and Manufacturing activities.
Scientific Advisory Board
Recce collaborates with experienced specialists who contribute to shaping our research initiatives and provide guidance on our clinical development programs.